The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share
Exploiting genotyping, DNA sequencing, imputation and trans-ancestral mapping, we used Bayesian and frequentist approaches to model the IRF5-TNPO3 locus association, now implicated in two immunotherapies and seven autoimmune diseases. Specifically, in systemic lupus erythematosus (SLE), we resolved...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2015
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24223
- Acceso en línea:
- https://doi.org/10.1093/hmg/ddu455
https://repository.urosario.edu.co/handle/10336/24223
- Palabra clave:
- Transcription factor
Transcription factor zbtb3
Unclassified drug
Dna binding protein
Interferon regulatory factor
Karyopherin beta
Allele
Ancestry group
Article
Autoimmune disease
Bayes theorem
Controlled study
Disease assessment
Dna sequence
European
Gene
Gene expression
Gene locus
Gene mapping
Genetic association
Genetic variability
Genotype
Haplotype
Human
Irf5 gene
Major clinical study
Primary biliary cirrhosis
Priority journal
Promoter region
Sjoegren syndrome
Systemic lupus erythematosus
Systemic sclerosis
Tnpo3 gene
Autoimmune disease
Case control study
Cohort analysis
Genetics
Male
Single nucleotide polymorphism
Systemic lupus erythematosus
Autoimmune diseases
Bayes theorem
Beta karyopherins
Case-control studies
Cohort studies
Dna-binding proteins
Haplotypes
Humans
Interferon regulatory factors
Male
systemic
single nucleotide
human
human
human
genetic
Irf5 protein
Tnpo3 protein
Zbtb3 protein
Lupus erythematosus
Polymorphism
Promoter regions
- Rights
- License
- Abierto (Texto Completo)
Summary: | Exploiting genotyping, DNA sequencing, imputation and trans-ancestral mapping, we used Bayesian and frequentist approaches to model the IRF5-TNPO3 locus association, now implicated in two immunotherapies and seven autoimmune diseases. Specifically, in systemic lupus erythematosus (SLE), we resolved separate associations in the IRF5 promoter (all ancestries) and with an extended European haplotype. We captured 3230 IRF5-TNPO3 high-quality, common variants across 5 ethnicities in 8395 SLE cases and 7367 controls. The genetic effect from the IRF5 promoter can be explained by any one of four variants in 5.7 kb (P-valuemeta = 6 × 10-49; OR = 1.38-1.97). The second genetic effect spanned an 85.5-kb, 24-variant haplotype that included the genes IRF5 and TNPO3(P-valuesEU = 10-27-10-32, OR = 1.7-1.81). Many variants at the IRF5 locus with previously assigned biological function are not members of either final credibleset of potential causal variants identified herein. In addition to the known biologically functional variants, we demonstrated that the risk allele of rs4728142, a variant in the promoter among the lowest frequentist probability and highest Bayesian posterior probability, was correlated with IRF5 expression and differentially binds the transcription factor ZBTB3. Our analytical strategy provides a novel framework for future studies aimed at dissecting etiological genetic effects. Finally, both SLE elements of the statistical model appear to operate in Sjögren's syndrome and systemic sclerosis whereas only the IRF5-TNPO3 gene-spanning haplotype is associated with primary biliary cirrhosis, demonstrating the nuance of similarity and difference in autoimmune disease risk mechanisms at IRF5-TNPO3. © The Author 2014. |
---|